EUCTR2004-001593-10-IT进行中（未招募）不适用
A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1)
MERCK S.P.A.0 个研究点开始时间: 2005年1月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2Treatment-Associated Dyskinesia in Parkinson's DiseaseEUCTR2004-001594-25-FIMerck KGaA600
进行中（未招募）
1 期
A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1) - PADDY 1Treatment-Associated Dyskinesia in Parkinson's DiseaseEUCTR2004-001593-10-GBMerck KGaA
进行中（未招募）
不适用
A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY 2EUCTR2004-001594-25-ATMerck KGaA600
进行中（未招募）
1 期
A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia. - PADDY-2Treatment-Associated Dyskinesia in Parkinson's DiseaseEUCTR2004-001594-25-ESMERCK KGaA
进行中（未招募）
不适用
A Clinical Trial to test whether TC-5619 improves symptoms for patients with stable schizophrenia if it is taken together with existing medicines.SchizophreniaEUCTR2011-005138-21-HUTargacept Inc.456